Treatment of circadian rhythm disorders

Abstract

Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

What is claimed is: 
     
       1. A method of treating a patient suffering from a circadian rhythm disorder, the method comprising internally administering to the patient tasimelteon in an amount effective to agonize MT1R and MT2R in the patient. 
     
     
       2. The method of  claim 1 , wherein the patient is light perception impaired (LPI). 
     
     
       3. The method of  claim 1 , wherein the patient is totally blind. 
     
     
       4. The method of  claim 1 , wherein the patient suffers from Non-24-Hour Sleep-Wake Disorder. 
     
     
       5. The method of  claim 1 , wherein the tasimelteon is effective to entrain the patient's cortisol circadian rhythm to a 24-hour circadian rhythm. 
     
     
       6. The method according to  claim 5 , wherein the 24-hour circadian rhythm comprises a 24-hour sleep-wake cycle in which the patient awakens at or near a target wake time following a daily sleep period of approximately 7 to 9 hours. 
     
     
       7. The method of  claim 1 , wherein the tasimelteon is effective to entrain the patient's melatonin circadian rhythm to a 24-hour circadian rhythm. 
     
     
       8. The method of  claim 1 , wherein the effective amount is between about 10 mg and about 100 mg per day. 
     
     
       9. The method of  claim 8 , wherein the effective amount is between about 20 mg and about 50 mg per day. 
     
     
       10. The method of  claim 9 , wherein the effective amount is about 20 mg per day.